22.07.2020 11:50
T3 Pharmaceuticals, a biotech company advancing immuno-oncology with its bacteria-based protein delivery platform, today announced the closing of its third financing round, raising over CHF 25M from existing investors. The proceeds will support the clinical development of lead the program, T3P-Y058-739, poised to enter clinical trials in 2021.